AMBLER, Pa., Aug. 9, 2011 /PRNewswire/ -- Allergy Technologies LLC, manufacturer of ActiveGuard™ mattress liners, is sponsoring a new bed bug research program at The Ohio State University through an initial $100,000+ grant provided by the Company.
This new endeavor will examine the importance and effects of specific products, protocols and strategies relating to innovative bed bug treatment applications. The dramatic rise in bed bug infestations throughout the country in the last ten years has created a need for more research to improve and expand pest management practices. Based on mutual agreement between The Ohio State University and Allergy Technologies, this grant provides a 2nd year renewal opportunity for an additional $100,000+ in funding.
According to Susan Jones, Ph.D., entomologist at The Ohio State University, the grant provided by Allergy Technologies will allow Jones and her urban entomology team to pursue sorely needed bed bug-related research leading to implementation of new and improved strategies for controlling bed bugs.
"This grant will enable us to embark upon important and in-depth research on product efficacy, treatment protocols, and application methods as we work to control bed bugs," said Dr. Jones. "With the current emergence of bed bug infestations, Allergy Technologies' sponsorship will allow us to pursue fundamental lab and applied field research. This programmatic research is geared toward investigating novel strategies in bed bug treatment leading to improved and effective solutions."
"We are proud to be able to support this university research. This grant evidences Allergy Technologies' continued commitment to developing bona fide research-based treatments aimed directly toward the bed bug scourge that is blanketing our country," stated Gus Carey, Managing Director of Allergy Technologies.
ActiveGuard by Allergy Technologies LLC, is a thin and breathable liner easily installed onto mattresses and box springs, which kill bed bugs and dust mites continuously for up to two years.
According to Joseph Latino, Director of Technical Services for Allergy Technologies, "We are highly optimistic that the findings from these studies will benefit the entire pest management industry toward reaching a common goal - establishing rigorous scientifically supported treatment options for controlling bed bugs."
Distinct from encasements and originally developed as a natural extension of the globally used mosquito nets by a team of research entomologists for use against dust mites, ActiveGuard has been extensively lab and field tested for use in both active and preventative bed bug control strategies.
About Allergy Technologies
Allergy Technologies is a subsidiary of A. Carey Co. LLC, which focuses on using philanthropy as a core business strategy for its businesses. Through its Philanprofit strategy, a portion of all ActiveGuard proceeds go to help fund inner-city homeless and women's shelters and asthma clinics.
For more information, call (866) 978-6288 or visit www.allergytechnologies.com.
SOURCE Allergy Technologies LLC